COVID-19: Novel coronavirus and IVC

The following dissertation on high dose intravenous Vitamin C in the supportive treatment of patients severely affected by the coronavirus (COVID –19) with pneumonia is not meant to infer that it is necessarily the best or only approach to the prevention and treatment of coronavirus (COVID-19) complications. It is causing worldwide concern, threatening to become a pandemic.

Before patients receive intravenous Vitamin C (IVC) they should have normal kidney function and normal G6PD levels. Vitamin C may also produce false positive glucose readings (both reducing agents) on glucometers so insulin dependent patients who have received IVC need to be assessed appropriately.

To read full report:  COVID-19: Novel coronavirus and IVCCurrent Guidelines and Clinical Trials